Half-year report · HY
4208.TEDINET S100X0R8
Period2025-04-01 → 2025-09-30
Filed2025-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥212.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥486.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥243.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥8.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥15.9bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.4bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.9bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥14.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥10.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥4.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥318m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥613m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥865.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥865.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥796.2bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥441.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥453.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥424.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥412.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥420.4bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥44.7bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥116.0bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥44.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥115.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥28.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥35.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥31.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥35.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥88.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥63.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥33.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥16.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥105.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥112.08 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-49.6 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.28 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥112.06 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥3.27 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 47.0% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-04-01 → 2025-09-30 | ¥16.7bn |
| Otherother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥23.6bn |
| Otherother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥6.9bn |
| Otherother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥2.1bn |
| High Performance Urethansreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥17.0bn |
| High Performance Urethansreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥16.8bn |
| High Performance Urethansreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥256m |
| High Performance Urethansreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥565m |
| Machinery And Metal Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥29.8bn |
| Machinery And Metal Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥29.6bn |
| Machinery And Metal Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥138m |
| Machinery And Metal Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Pharmaceuticalreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥10.5bn |
| Pharmaceuticalreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥10.5bn |
| Pharmaceuticalreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| Pharmaceuticalreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥483m |
| Polymers And Chemicalsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥118.5bn |
| Polymers And Chemicalsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥107.5bn |
| Polymers And Chemicalsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥11.0bn |
| Polymers And Chemicalsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.2bn |
| Specialty Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥29.8bn |
| Specialty Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥24.7bn |
| Specialty Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Specialty Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.3bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥222.3bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥212.7bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9.6bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥10.3bn |
| Otherother segments | revenue | 2024-04-01 → 2024-09-30 | ¥20.7bn |
| Otherother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥25.0bn |
| Otherother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥4.4bn |
| Otherother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥13.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥13.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.9bn |
| High Performance Urethansreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| High Performance Urethansreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.1bn |
| High Performance Urethansreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥229m |
| High Performance Urethansreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥774m |
| Machinery And Metal Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥43.0bn |
| Machinery And Metal Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥42.8bn |
| Machinery And Metal Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥282m |
| Machinery And Metal Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Pharmaceuticalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.9bn |
| Pharmaceuticalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.0bn |
| Pharmaceuticalreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥815m |
| Pharmaceuticalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥712m |
| Polymers And Chemicalsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥137.8bn |
| Polymers And Chemicalsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥128.7bn |
| Polymers And Chemicalsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.1bn |
| Polymers And Chemicalsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2.5bn |
| Specialty Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.7bn |
| Specialty Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥24.4bn |
| Specialty Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥7.3bn |
| Specialty Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.0bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥256.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥243.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥13.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 574
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01002-000PharmaceuticalReportableSegmentsMember | 815000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 9080000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01002-000MachineryAndMetalProductsReportableSegmentsMember | 282000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_OtherReportableSegmentsMember | -4362000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 13335000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -13335000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01002-000SpecialtyProductsReportableSegmentsMember | 31677000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 7364000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01002-000PharmaceuticalReportableSegmentsMember | 15860000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 137752000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01002-000MachineryAndMetalProductsReportableSegmentsMember | 43041000000 | JPY |
| Net sales | Prior1InterimDuration_OtherReportableSegmentsMember | 20680000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 256374000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -13335000000 | JPY |
| Net sales | Prior1InterimDuration | 243039000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01002-000SpecialtyProductsReportableSegmentsMember | 4960000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 774000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01002-000PharmaceuticalReportableSegmentsMember | 712000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01002-000PolymersAndChemicalsReportableSegmentsMember | -2477000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01002-000MachineryAndMetalProductsReportableSegmentsMember | 2973000000 | JPY |
| Operating income | Prior1InterimDuration_OtherReportableSegmentsMember | 1029000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 7971000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -1922000000 | JPY |
| Operating income | Prior1InterimDuration | 6049000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01002-000SpecialtyProductsReportableSegmentsMember | 24701000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 16781000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01002-000PharmaceuticalReportableSegmentsMember | 10475000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 107516000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01002-000MachineryAndMetalProductsReportableSegmentsMember | 29636000000 | JPY |
| Revenues from external customers | InterimDuration_OtherReportableSegmentsMember | 23595000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 212704000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 212704000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01002-000SpecialtyProductsReportableSegmentsMember | 5115000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 256000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01002-000PharmaceuticalReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 11013000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01002-000MachineryAndMetalProductsReportableSegmentsMember | 138000000 | JPY |
| Transactions with other segments | InterimDuration_OtherReportableSegmentsMember | -6908000000 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 9615000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -9615000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01002-000SpecialtyProductsReportableSegmentsMember | 29816000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 17037000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01002-000PharmaceuticalReportableSegmentsMember | 10476000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 118529000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01002-000MachineryAndMetalProductsReportableSegmentsMember | 29774000000 | JPY |
| Net sales | InterimDuration_OtherReportableSegmentsMember | 16687000000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 222319000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |